Compare TKLF & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | ASBP |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.8M |
| IPO Year | 2020 | 2021 |
| Metric | TKLF | ASBP |
|---|---|---|
| Price | $1.75 | $7.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.9K | ★ 26.6K |
| Earning Date | 12-19-2025 | 04-08-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.69 | $0.05 |
| 52 Week High | $4.32 | $8.18 |
| Indicator | TKLF | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 61.10 |
| Support Level | $1.78 | $0.16 |
| Resistance Level | $2.39 | N/A |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 25.01 | 96.38 |
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.